Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2022

In 2022, Anika Therapeutics Inc.'s disclosed short interest ran from 7.74% of shares outstanding on 14 Jan 2022 to 4.49% on 30 Dec 2022, a change of -3.25 percentage points. The year's high was 8.15% on 15 Mar 2022 and its low 4.01% on 15 Dec 2022, averaging 6.95% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.91 days on 14 Apr 2022. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2022

2022 in figures

Start of year
7.74% (14 Jan 2022)
End of year
4.49% (30 Dec 2022)
Change
-3.25 pp
High
8.15% (15 Mar 2022)
Low
4.01% (15 Dec 2022)
Average
6.95%
Highest days to cover
15.91 (14 Apr 2022)
SEC filings marked
8

Every report in 2022

Anika Therapeutics Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.74%9.69
31 Jan 20227.68%13.61
15 Feb 20227.90%13.13
28 Feb 20227.79%15.78
15 Mar 20228.15%13.01results (8-K), 10-K filed
31 Mar 20227.84%15.20
14 Apr 20227.53%15.91
29 Apr 20227.50%14.89
13 May 20227.26%7.33results (8-K), 10-Q filed
31 May 20227.28%12.14
15 Jun 20227.81%9.72
30 Jun 20227.24%6.27
15 Jul 20227.19%13.23
29 Jul 20227.03%15.24
15 Aug 20226.83%11.66results (8-K), 10-Q filed
31 Aug 20226.59%13.96
15 Sep 20226.28%11.91
30 Sep 20226.78%9.49
14 Oct 20226.81%11.80
31 Oct 20226.76%11.89
15 Nov 20226.55%8.06results (8-K), 10-Q filed
30 Nov 20225.80%10.53
15 Dec 20224.01%5.92
30 Dec 20224.49%4.29

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.